{"id":3006,"date":"2019-07-18T00:00:00","date_gmt":"2021-03-18T06:14:28","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=3006"},"modified":"2021-03-18T14:14:28","modified_gmt":"2021-03-18T06:14:28","slug":"eisai-presents-research-evaluating-correlation-of-highly-precisely-measured-amyloid-beta-in-plasma-and-cerebrospinal-fluid-with-newly-developed-automated-protein-assay-system-at-alzheimers-as","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2019\/07\/18\/eisai-presents-research-evaluating-correlation-of-highly-precisely-measured-amyloid-beta-in-plasma-and-cerebrospinal-fluid-with-newly-developed-automated-protein-assay-system-at-alzheimers-as\/","title":{"rendered":"EISAI PRESENTS RESEARCH EVALUATING CORRELATION OF HIGHLY-PRECISELY MEASURED AMYLOID BETA IN PLASMA AND CEREBROSPINAL FLUID WITH NEWLY DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM AT ALZHEIMER\u2019S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019"},"content":{"rendered":"<p>Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, &#8220;Eisai&#8221;) announced its latest research on evaluation about correlation of amyloid beta (A\u03b2) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation (Headquarters: Hyogo, Chairman and CEO: Hisashi Ietsugu, &#8220;Sysmex&#8221;), using full-automated immunoassay system HISCL<sup>TM*1<\/sup>\u00a0series for creating the simplified diagnosis of Alzheimer\u2019s disease (AD) with blood was presented at the Alzheimer\u2019s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019. (Poster Presentation No.: P4-548)<\/p>\n<p>A\u03b2 is a peptide consisting of amino acid residues, which is generated by excision from the amyloid precursor protein. \u00a0A\u03b2<sub>1-40<\/sub>\u00a0consisting of 40 residues is dominant substance, and A\u03b2<sub>1-40\u00a0<\/sub>does not significantly fluctuate with progression of AD. On the other hand, as for the A\u03b2<sub>1-42<\/sub>\u00a0consisting of 42 residues, the aggregability is high and the reduction in A\u03b2<sub>1-42\u00a0<\/sub>is detected from the early stage of AD. The absolute value of A\u03b2 has individual differences and intra individual variabilities, therefore, A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0ratio in CSF is used for the diagnosis of amyloid positive or negative.<\/p>\n<p>In this research, the correlation between A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0ratio in plasma and A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0in CSF were investigated for creating a simple blood diagnostic for AD by the automated protein assay system using full-automated immunoassay system HISCL\u2122series. This assay system enables the automated immune assay in 17 minutes with small volume samples such as 10-30\u00b5L, and A\u03b2 assay in plasmas is possible with enough sensitivity and the high reliability. The samples from elderly person with normal cognition and patients with mild cognitive impairment (MCI) and AD were used for investigation with HISCL\u2122<sup>\u00a0<\/sup>series. Results show a correlation (Spearman\u2019s rank correlation coefficient (r<sub>s<\/sub>) *<sup>2<\/sup>\u00a0=0.502, p&lt;0.001) between A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-4\u00a0<\/sub>ratio in plasma and A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0ratio in CSF; therefore, it may be possible to understand the pathological processes in the brain condition by measuring A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0ratio in plasma. To further assess clinical utility, Eisai aim to check the correlation between A\u03b2<sub>1-42<\/sub>\/A\u03b2<sub>1-40<\/sub>\u00a0ratio in plasma and amyloid PET.<\/p>\n<p>Eisai aims to realize the prevention and cure of dementia including establishment of new diagnostics by multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of Alzheimer\u2019s disease and dementia. Eisai strives further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.<\/p>\n<p>&nbsp;<\/p>\n<p><sup>*1<\/sup>\u00a0HISCL\u2122 is a trademark of Sysmex Corporation.<\/p>\n<p><sup>*2<\/sup>\u00a0The correlation coefficient indicates the strength of the relationship between the two data from the two quantitative data distributions. In this analysis, Spearman\u2019s rank correlation coefficient (r<sub>s<\/sub>) which is an index of correlation obtained from rank data is calculated.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span class=\"txt-b\">Media Inquiries:<\/span><\/strong><br \/>\nPublic Relations Department,<br \/>\nEisai Co., Ltd.<br \/>\n+81-(0)3-3817-5120<\/p>\n<p>&nbsp;<\/p>\n<p><b>[Notes to editors]<\/b><br \/>\n<b>1.<\/b><b>\u00a0About collaboration between Eisai and Sysmex<\/b><br \/>\nEisai and Sysmex have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia in February, 2016. Leveraging each other\u2019s technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, &#8220;Eisai&#8221;) announced its latest research on evaluation about correlation of amyloid beta (A\u03b2) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation (Headquarters: Hyogo, Chairman and CEO: Hisashi Ietsugu, &#8220;Sysmex&#8221;), using full-automated immunoassay system HISCLTM*1\u00a0series for creating the simplified diagnosis of Alzheimer\u2019s disease (AD) with blood was presented at the Alzheimer\u2019s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019. (Poster Presentation No.: P4-548)<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-3006","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3006"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=3006"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3006\/revisions"}],"predecessor-version":[{"id":3008,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3006\/revisions\/3008"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=3006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=3006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=3006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}